SG10201401941RA - Combinations Of An Anti-Her2 Antibody-Drug Conjugate And Chemotherapeutic Agents, And Methods Of Use - Google Patents

Combinations Of An Anti-Her2 Antibody-Drug Conjugate And Chemotherapeutic Agents, And Methods Of Use

Info

Publication number
SG10201401941RA
SG10201401941RA SG10201401941RA SG10201401941RA SG10201401941RA SG 10201401941R A SG10201401941R A SG 10201401941RA SG 10201401941R A SG10201401941R A SG 10201401941RA SG 10201401941R A SG10201401941R A SG 10201401941RA SG 10201401941R A SG10201401941R A SG 10201401941RA
Authority
SG
Singapore
Prior art keywords
combinations
methods
chemotherapeutic agents
drug conjugate
her2 antibody
Prior art date
Application number
SG10201401941RA
Inventor
Leanne Berry
Gail Lewis Phillips
Mark X Sliwkowski
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40858064&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201401941R(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of SG10201401941RA publication Critical patent/SG10201401941RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
SG10201401941RA 2008-03-18 2009-03-10 Combinations Of An Anti-Her2 Antibody-Drug Conjugate And Chemotherapeutic Agents, And Methods Of Use SG10201401941RA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3741008P 2008-03-18 2008-03-18

Publications (1)

Publication Number Publication Date
SG10201401941RA true SG10201401941RA (en) 2014-07-30

Family

ID=40858064

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10202104314YA SG10202104314YA (en) 2008-03-18 2009-03-10 Combinations Of An Anti-Her2 Antibody-Drug Conjugate And Chemotherapeutic Agents, And Methods Of Use
SG10201401941RA SG10201401941RA (en) 2008-03-18 2009-03-10 Combinations Of An Anti-Her2 Antibody-Drug Conjugate And Chemotherapeutic Agents, And Methods Of Use
SG10201401942PA SG10201401942PA (en) 2008-03-18 2009-03-10 Combinations Of An Anti-Her2 Antibody-Drug Conjugate And Chemotherapeutic Agents, And Methods Of Use

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10202104314YA SG10202104314YA (en) 2008-03-18 2009-03-10 Combinations Of An Anti-Her2 Antibody-Drug Conjugate And Chemotherapeutic Agents, And Methods Of Use

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201401942PA SG10201401942PA (en) 2008-03-18 2009-03-10 Combinations Of An Anti-Her2 Antibody-Drug Conjugate And Chemotherapeutic Agents, And Methods Of Use

Country Status (29)

Country Link
US (5) US8663643B2 (en)
EP (6) EP2644204B1 (en)
JP (5) JP5656823B2 (en)
KR (8) KR20230054478A (en)
CN (5) CN104888231B (en)
AR (1) AR070865A1 (en)
AU (1) AU2009225877B2 (en)
BR (1) BRPI0906181A2 (en)
CA (3) CA2990929C (en)
CL (1) CL2009000559A1 (en)
CR (2) CR20180483A (en)
DK (3) DK2254571T3 (en)
ES (4) ES2629405T3 (en)
HK (1) HK1147444A1 (en)
HU (3) HUE035182T2 (en)
IL (7) IL295098A (en)
MA (1) MA32223B1 (en)
MX (3) MX2010010168A (en)
MY (4) MY166446A (en)
NZ (4) NZ587706A (en)
PH (4) PH12014502133A1 (en)
PL (4) PL2644194T3 (en)
RU (2) RU2510272C2 (en)
SG (3) SG10202104314YA (en)
SI (3) SI2644204T1 (en)
TW (4) TWI527593B (en)
UA (2) UA127472C2 (en)
WO (1) WO2009117277A2 (en)
ZA (1) ZA201006186B (en)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006506317A (en) 2002-01-11 2006-02-23 バイオマリン ファーマシューティカル インコーポレイテッド Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
MXPA06014065A (en) * 2004-06-01 2007-01-31 Genentech Inc Antibody drug conjugates and methods.
JO3000B1 (en) 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
BRPI0606542A8 (en) * 2005-02-23 2018-03-20 Genentech Inc methods to increase the time to disease progression (ttp)
CA2677108A1 (en) 2007-03-02 2008-09-12 Genentech, Inc. Predicting response to a her inhibitor
TWI472339B (en) 2008-01-30 2015-02-11 Genentech Inc Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof
BRPI0812682A2 (en) 2008-06-16 2010-06-22 Genentech Inc metastatic breast cancer treatment
DK2322221T3 (en) 2008-08-05 2014-09-01 Toray Industries PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PREVENTION OF CANCER
MX2011001445A (en) 2008-08-05 2011-04-05 Toray Industries Cancer detection method.
KR101781654B1 (en) 2009-03-12 2017-09-25 제넨테크, 인크. Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies
US20110165155A1 (en) * 2009-12-04 2011-07-07 Genentech, Inc. Methods of treating metastatic breast cancer with trastuzumab-mcc-dm1
US9682991B2 (en) 2009-12-31 2017-06-20 Fundación Centro Nacional De Investigaciones Oncologicas Carlos Iii Tricyclic compounds for use as kinase inhibitors
WO2011096534A1 (en) 2010-02-04 2011-08-11 東レ株式会社 Pharmaceutical composition for treatment and/or prevention of cancer
KR101854484B1 (en) * 2010-11-08 2018-05-03 노파르티스 아게 Use of 2-carboxamide cycloamino urea derivatives in the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members
JP2014502596A (en) * 2010-12-09 2014-02-03 ジェネンテック， インコーポレイテッド Treatment of HER2-positive cancer with paclitaxel and trastuzumab-MCC-DM1
WO2012098387A1 (en) 2011-01-18 2012-07-26 Centro Nacional De Investigaciones Oncológicas (Cnio) 6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
PT2717917T (en) 2011-07-05 2016-07-27 Bioasis Technologies Inc P97-antibody conjugates
RU2624040C2 (en) 2011-08-04 2017-06-30 Торэй Индастриз, Инк. Method for pancreatic cancer detection
US9409993B2 (en) 2011-08-04 2016-08-09 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of pancreatic cancer
HUE047006T2 (en) 2011-08-04 2020-04-28 Toray Industries Pharmaceutical composition comprising anti caprin-1 antibodies for treating and/or preventing cancer
EP2739649B1 (en) 2011-08-05 2017-09-27 Bioasis Technologies Inc. P97 fragments with transfer activity
RU2603462C2 (en) 2011-10-13 2016-11-27 Дженентек, Инк. Treatment of pharmacologically induced hypacidity
KR102099991B1 (en) 2011-10-14 2020-04-14 제넨테크, 인크. Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab
ES2739380T3 (en) 2012-02-21 2020-01-30 Toray Industries Pharmaceutical composition for cancer treatment
WO2013125630A1 (en) 2012-02-21 2013-08-29 東レ株式会社 Pharmaceutical composition for treatment and/or prevention of cancer
IN2014KN01715A (en) 2012-02-21 2015-10-23 Toray Industries
PT2818482T (en) 2012-02-21 2019-08-06 Toray Industries Pharmaceutical composition for treatment of cancer
RU2018138976A (en) * 2012-03-23 2018-12-06 Эррэй Биофарма Инк. BRAIN CANCER TREATMENT
RU2640245C2 (en) 2012-03-30 2017-12-27 Торэй Индастриз, Инк. Pharmaceutical composition for liver cancer treatment and/or prevention
JP6107655B2 (en) 2012-03-30 2017-04-05 東レ株式会社 Pharmaceutical composition for treatment and / or prevention of gallbladder cancer
TW201843172A (en) * 2012-06-25 2018-12-16 美商再生元醫藥公司 Anti-egfr antibodies and uses thereof
CN112587658A (en) * 2012-07-18 2021-04-02 博笛生物科技有限公司 Targeted immunotherapy for cancer
HUE043162T2 (en) 2012-07-19 2019-08-28 Toray Industries Method for detecting cancer
ES2769831T3 (en) 2012-07-19 2020-06-29 Toray Industries Cancer detection method
WO2014022515A1 (en) 2012-07-31 2014-02-06 Bioasis Technologies, Inc. Dephosphorylated lysosomal storage disease proteins and methods of use thereof
WO2014055634A1 (en) * 2012-10-02 2014-04-10 Yale University Identification of small molecule inhibitors of jumonji at-rich interactive domain 1a (jarid1a) and 1b (jarid1b) histone demethylase
KR102291355B1 (en) * 2012-11-30 2021-08-19 에프. 호프만-라 로슈 아게 Identification of patients in need of pd-l1 inhibitor cotherapy
WO2014138186A1 (en) * 2013-03-05 2014-09-12 The Johns Hopkins University Bioorthogonal two-component delivery systems for enhanced internalization of nanotherapeutics
WO2014160438A1 (en) 2013-03-13 2014-10-02 Bioasis Technologies Inc. Fragments of p97 and uses thereof
EP2968591A1 (en) * 2013-03-15 2016-01-20 Novartis AG Cell proliferation inhibitors and conjugates thereof
MA38496B2 (en) 2013-03-15 2021-01-29 Regeneron Pharma Biologically active molecules, their conjugates, and therapeutic uses
MY173295A (en) 2013-04-16 2020-01-14 Genentech Inc Pertuzumab variants and evaluation thereof
HUE042081T2 (en) 2013-08-09 2019-06-28 Toray Industries Pharmaceutical composition for treatment and/or prevention of cancer
WO2015031396A1 (en) 2013-08-26 2015-03-05 Regeneron Pharmaceuticals, Inc. Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses
CN110240655B (en) * 2013-11-19 2023-05-16 荣昌生物制药(烟台)股份有限公司 anti-HER 2 antibodies and conjugates thereof
CN105829299A (en) 2013-11-19 2016-08-03 普渡研究基金会 Anti-cancer agents and preparation thereof
SG11201605455YA (en) 2014-01-10 2016-08-30 Birdie Biopharmaceuticals Inc Compounds and compositions for treating egfr expressing tumors
BR112016013482B1 (en) * 2014-01-31 2022-04-19 Daiichi Sankyo Company, Limited ANTI-HER2-DRUG ANTIBODY CONJUGATE, ANTI-TUMOR AND/OR ANTI-CANCER DRUGS AND PHARMACEUTICAL COMPOSITION
CA2935195A1 (en) 2014-02-03 2015-08-06 Bioasis Technologies, Inc. P97 fusion proteins
AU2015219339B2 (en) 2014-02-19 2020-03-05 Bioasis Technologies Inc. P97-IDS fusion proteins
JP2017514806A (en) * 2014-04-16 2017-06-08 シグナル ファーマシューティカルズ，エルエルシー Methods of treating cancer using TOR kinase inhibitor combination therapy
WO2015164665A1 (en) 2014-04-25 2015-10-29 Genentech, Inc. Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab
WO2015168521A2 (en) 2014-05-01 2015-11-05 Bioasis Technologies, Inc. P97-polynucleotide conjugates
SG11201610880RA (en) 2014-06-30 2017-01-27 Tarveda Therapeutics Inc Targeted conjugates and particles and formulations thereof
CN105440135A (en) 2014-09-01 2016-03-30 博笛生物科技有限公司 Anti-PD-L1 conjugate for treating tumors
AU2015286043B2 (en) 2014-07-09 2020-08-20 Birdie Biopharmaceuticals Inc. Anti-PD-L1 combinations for treating tumors
WO2016061231A1 (en) * 2014-10-14 2016-04-21 Deciphera Pharmaceuticals, Llc Inhibition of tumor cell interactions with the microenvironment resulting in a reduction in tumor growth and disease progression
WO2016196373A2 (en) 2015-05-30 2016-12-08 Genentech, Inc. Methods of treating her2-positive metastatic breast cancer
CN113607945A (en) * 2015-07-07 2021-11-05 豪夫迈·罗氏有限公司 Combination therapy of an anti-HER 2 antibody-drug conjugate and a Bcl-2 inhibitor
EP3331573A4 (en) * 2015-08-06 2019-02-27 City of Hope Therapeutic cell internalizing conjugates
CN108473538B (en) * 2015-10-28 2022-01-28 塔弗达治疗有限公司 SSTR targeting conjugates and particles and formulations thereof
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
CN106729743B (en) * 2015-11-23 2021-09-21 四川科伦博泰生物医药股份有限公司 anti-ErbB 2 antibody-drug conjugate, and composition, preparation method and application thereof
RU2618405C1 (en) * 2015-12-31 2017-05-03 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Method for adjuvant chemotherapy duration determination in case of locally advanced colorectal cancer with metastases in regional lymph nodes after radical surgery
CN106943598A (en) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 Anti- HER2 for treating tumour is combined
CN115554406A (en) 2016-01-07 2023-01-03 博笛生物科技有限公司 anti-CD 20 combinations for the treatment of tumors
CN115252792A (en) 2016-01-07 2022-11-01 博笛生物科技有限公司 anti-EGFR combinations for the treatment of tumors
CA3011440A1 (en) 2016-01-25 2017-08-03 Regeneron Pharmaceuticals, Inc. Maytansinoid derivatives, conjugates thereof, and methods of use
KR102646702B1 (en) 2016-09-23 2024-03-11 퍼듀 리서치 파운데이션 Anticancer drugs and their preparation
US20180140703A1 (en) * 2016-11-18 2018-05-24 The Regents Of The University California Tumor radiosensitization with antibody conjugates
WO2018107069A1 (en) * 2016-12-08 2018-06-14 Washington University Incompatible blood group antigen for cancer detection and treatment
JP7244987B2 (en) 2016-12-14 2023-03-23 シージェン インコーポレイテッド Multidrug Antibody Drug Conjugates
TW202138007A (en) 2017-01-17 2021-10-16 美商建南德克公司 Subcutaneous her2 antibody formulations
WO2018160538A1 (en) * 2017-02-28 2018-09-07 Mersana Therapeutics, Inc. Combination therapies of her2-targeted antibody-drug conjugates
EP3589661B1 (en) 2017-03-02 2023-11-01 Genentech, Inc. Adjuvant treatment of her2-positive breast cancer
EP3612234B1 (en) * 2017-04-20 2024-03-13 ADC Therapeutics SA Combination therapy with an anti-axl antibody-drug conjugate
CN108794467A (en) 2017-04-27 2018-11-13 博笛生物科技有限公司 2- amino-quinoline derivatives
AU2018258663B2 (en) 2017-04-28 2022-08-04 Seagen Inc. Treatment of HER2 positive cancers
CA3066350A1 (en) * 2017-06-06 2018-12-13 The Johns Hopkins University Induction of synthetic lethality with epigenetic therapy
US11517567B2 (en) 2017-06-23 2022-12-06 Birdie Biopharmaceuticals, Inc. Pharmaceutical compositions
SG10201801219VA (en) 2018-02-13 2019-09-27 Agency Science Tech & Res Anti-HER2 Antibodies
KR20200034369A (en) 2018-09-21 2020-03-31 건국대학교 글로컬산학협력단 Antibody fragments specifically binding to Her2 and uses thereof
US10966950B2 (en) 2019-06-11 2021-04-06 Io Therapeutics, Inc. Use of an RXR agonist in treating HER2+ cancers
KR20220019724A (en) * 2019-06-11 2022-02-17 아이오 테라퓨틱스, 인크. Use of RXR agonists in the treatment of HER2+ cancer
WO2021030665A1 (en) * 2019-08-15 2021-02-18 Silverback Therapeutics, Inc. Formulations of benzazepine conjugates and uses thereof
US20220387618A1 (en) 2019-11-15 2022-12-08 Seagen Inc. Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate
JP2023512446A (en) * 2020-01-13 2023-03-27 アプティーボ リサーチ アンド デベロップメント エルエルシー Methods and compositions for preventing adsorption of therapeutic proteins to drug delivery system components
US20230295342A1 (en) * 2020-07-22 2023-09-21 Eric POMA Clinical methods for use of her2 binding molecules
CA3231639A1 (en) * 2021-09-15 2023-03-23 Larry Weisenthal Triple-agent therapy for cancer treatment
WO2023108012A1 (en) 2021-12-07 2023-06-15 Io Therapeutics, Inc. Use of an rxr agonist and taxanes in treating her2+ cancers

Family Cites Families (142)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2802005A (en) 1957-08-06 S-eluorourace
US2885396A (en) 1957-03-21 1959-05-05 Heidelberger Charles N-glycosides of 5-fluorouracil
CH588505A5 (en) 1972-06-08 1977-06-15 Research Corp
US3896111A (en) 1973-02-20 1975-07-22 Research Corp Ansa macrolides
US4151042A (en) 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
US4137230A (en) 1977-11-14 1979-01-30 Takeda Chemical Industries, Ltd. Method for the production of maytansinoids
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4265814A (en) 1978-03-24 1981-05-05 Takeda Chemical Industries Matansinol 3-n-hexadecanoate
JPS5562090A (en) 1978-10-27 1980-05-10 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US5206018A (en) 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55164687A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS5566585A (en) 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS55164685A (en) 1979-06-08 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164686A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4309428A (en) 1979-07-30 1982-01-05 Takeda Chemical Industries, Ltd. Maytansinoids
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US5169774A (en) 1984-02-08 1992-12-08 Cetus Oncology Corporation Monoclonal anti-human breast cancer antibodies
US4753894A (en) 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
US5583024A (en) 1985-12-02 1996-12-10 The Regents Of The University Of California Recombinant expression of Coleoptera luciferase
US4956453A (en) 1985-12-06 1990-09-11 Cetus Corporation Anti-human ovarian cancer immunotoxins and methods of use thereof
CA1289880C (en) 1985-12-06 1991-10-01 Jeffrey L. Winkelhake Anti-human ovarian cancer immunotoxins and methods of use thereof
US7838216B1 (en) 1986-03-05 2010-11-23 The United States Of America, As Represented By The Department Of Health And Human Services Human gene related to but distinct from EGF receptor gene
US5395924A (en) 1986-03-20 1995-03-07 Dana-Farber Cancer Institute, Inc. Blocked lectins; methods and affinity support for making the same using affinity ligands; and method of killing selected cell populations having reduced non-selective cytotoxicity
FR2601675B1 (en) 1986-07-17 1988-09-23 Rhone Poulenc Sante TAXOL DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US4981979A (en) 1987-09-10 1991-01-01 Neorx Corporation Immunoconjugates joined by thioether bonds having reduced toxicity and improved selectivity
US5824311A (en) 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
US5217713A (en) 1988-12-27 1993-06-08 Takeda Chemical Industries, Ltd. Cytotoxic bispecific monoclonal antibody, its production and use
US5705157A (en) 1989-07-27 1998-01-06 The Trustees Of The University Of Pennsylvania Methods of treating cancerous cells with anti-receptor antibodies
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
DE4014540A1 (en) 1990-05-07 1991-11-14 Klaus Dr Tschaikowsky Immune conjugates for prophylaxis and treatment of organ damage - caused by inflammation, esp. sepsis, contain monoclonal antibody, crosslinker and enzyme inhibitor of protein kinase C or calcium antagonist
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
IL101943A0 (en) 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
LU91067I2 (en) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab and its variants and immunochemical derivatives including immotoxins
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
US5750561A (en) 1991-07-08 1998-05-12 Rhone-Poulenc Rorer, S.A. Compositions containing taxane derivatives
US5698582A (en) 1991-07-08 1997-12-16 Rhone-Poulenc Rorer S.A. Compositions containing taxane derivatives
US5714512A (en) 1991-07-08 1998-02-03 Rhone-Poulenc Rorer, S.A. Compositions containing taxane derivatives
EP0656367A1 (en) 1991-08-22 1995-06-07 Becton, Dickinson and Company Method and composition for cancer therapy and for prognosticating responses to cancer theraphy
US6022541A (en) 1991-10-18 2000-02-08 Beth Israel Deaconess Medical Center Immunological preparation for concurrent specific binding to spatially exposed regions of vascular permeability factor bound in-vivo to a tumor associated blood vessel
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
DE69231123T2 (en) 1992-03-25 2001-02-15 Immunogen Inc Conjugates of cell-binding agents and derivatives of CC-1065
US7754211B2 (en) 1992-04-10 2010-07-13 Research Development Foundation Immunotoxins directed against c-erbB-2(HER-2/neu) related surface antigens
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
FR2698543B1 (en) 1992-12-02 1994-12-30 Rhone Poulenc Rorer Sa New taxoid-based compositions.
JP3161490B2 (en) 1993-07-30 2001-04-25 松下電器産業株式会社 Mold equipment
US5679648A (en) 1994-11-30 1997-10-21 The University Hospital Methods for the treatment and prevention of fungal infections by administration of 3'-deoxypurine nucleosides
JPH08336393A (en) 1995-04-13 1996-12-24 Mitsubishi Chem Corp Production of optically active gamma-substituted-beta-hydroxybutyric ester
US5837234A (en) 1995-06-07 1998-11-17 Cytotherapeutics, Inc. Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US5919815A (en) 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
WO1997044407A1 (en) 1996-05-23 1997-11-27 Ian Alexander Gilmour Process for extraction of proanthocyanidins from botanical material
CA2702219C (en) 1996-11-06 2013-01-08 Sequenom, Inc. High density immobilization of nucleic acids
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
AU743758B2 (en) 1997-04-07 2002-02-07 Genentech Inc. Anti-VEGF antibodies
US6602677B1 (en) 1997-09-19 2003-08-05 Promega Corporation Thermostable luciferases and methods of production
US6391311B1 (en) 1998-03-17 2002-05-21 Genentech, Inc. Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1
RS49779B (en) 1998-01-12 2008-06-05 Glaxo Group Limited, Byciclic heteroaromatic compounds as protein tyrosine kinase inhibitors
ES2261589T3 (en) 1998-05-06 2006-11-16 Genentech, Inc. ANTI-HER2 ANTIBODY COMPOSITION.
ES2524141T3 (en) 1999-04-01 2014-12-04 Talon Therapeutics, Inc. Compositions to treat cancer
KR100816572B1 (en) 1999-04-28 2008-03-24 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 Anti-VEGF antibody and a pharmaceutical composition comprising the same
US6656730B1 (en) 1999-06-15 2003-12-02 Isis Pharmaceuticals, Inc. Oligonucleotides conjugated to protein-binding drugs
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
CN101518653B (en) * 1999-06-25 2015-08-19 基因技术股份有限公司 Use the Therapeutic Method of anti-ErbB antibody-maytansinoid conjugate
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
DK1189634T3 (en) 1999-06-25 2007-06-25 Genentech Inc Treatment of prostate cancer with anti-ErbB2 antibodies
JP4780633B2 (en) 1999-06-25 2011-09-28 イムノゲン インコーポレーティッド Method of treatment using anti-ErbB antibody-maytansinoid complex
US6933299B1 (en) 1999-07-09 2005-08-23 Smithkline Beecham Corporation Anilinoquinazolines as protein tyrosine kinase inhibitors
WO2001004111A1 (en) 1999-07-09 2001-01-18 Glaxo Group Limited Anilinoquinazolines as protein tyrosine kinase inhibitors
US6531131B1 (en) 1999-08-10 2003-03-11 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for Neisseria meningitidis
US6635677B2 (en) * 1999-08-13 2003-10-21 Case Western Reserve University Methoxyamine combinations in the treatment of cancer
KR20110008112A (en) 1999-08-27 2011-01-25 제넨테크, 인크. Dosages for treatment with anti-erbb2 antibodies
US7030231B1 (en) 1999-09-30 2006-04-18 Catalyst Biosciences, Inc. Membrane type serine protease 1 (MT-SP1) and uses thereof
US7303749B1 (en) 1999-10-01 2007-12-04 Immunogen Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
JP4776843B2 (en) 1999-10-01 2011-09-21 イムノゲン インコーポレーティッド Cancer composition and method using immunoconjugate and chemotherapeutic agent
NZ517772A (en) 1999-11-24 2004-03-26 Immunogen Inc Cytotoxic agents comprising taxanes and their therapeutic use
US6632979B2 (en) 2000-03-16 2003-10-14 Genentech, Inc. Rodent HER2 tumor model
US7097840B2 (en) * 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
TW200914443A (en) 2000-06-30 2009-04-01 Glaxo Group Ltd Process for preparing substituted quinazolinyl furanaldehyde
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
JP4450555B2 (en) 2000-12-28 2010-04-14 協和発酵キリン株式会社 New monoclonal antibody
EP1353693B1 (en) 2001-01-16 2005-03-16 Glaxo Group Limited Pharmaceutical combination containing a 4-quinazolineamine and paclitaxel, carboplatin or vinorelbine for the treatment of cancer
US20030103985A1 (en) 2001-05-18 2003-06-05 Boehringer Ingelheim International Gmbh Cytotoxic CD44 antibody immunoconjugates
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
PT2000545E (en) * 2001-06-20 2011-12-21 Genentech Inc Compositions and methods for the diagnosis and treatment of lung tumor
US20040235068A1 (en) 2001-09-05 2004-11-25 Levinson Arthur D. Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
US20080085283A1 (en) 2001-09-05 2008-04-10 Levinson Arthur D Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
WO2005063299A2 (en) 2003-12-24 2005-07-14 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
US20050238650A1 (en) 2002-04-17 2005-10-27 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
US6790954B2 (en) 2002-01-29 2004-09-14 Immunogen, Inc. Mutant Actinosynnema pretiosum strain with increased maytansinoid production
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
CA2491017A1 (en) 2002-07-03 2004-01-15 Immunogen, Inc. Antibodies to non-shed muc1 and muc16, and uses thereof
AU2003259163B2 (en) 2002-08-16 2008-07-03 Immunogen, Inc. Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs
US20040126379A1 (en) 2002-08-21 2004-07-01 Boehringer Ingelheim International Gmbh Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents
US20040120949A1 (en) 2002-11-08 2004-06-24 Boehringer Ingelheim International Gmbh Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and radiotherapy
CA2506320A1 (en) 2002-11-21 2004-06-10 Genentech, Inc. Therapy of non-malignant diseases or disorders with anti-erbb2 antibodies
US7432088B2 (en) 2003-05-08 2008-10-07 Immunogen Inc. Methods for the production of ansamitocins
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
CN1816356A (en) 2003-05-14 2006-08-09 免疫原公司 Drug conjugate composition
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
US7297709B2 (en) 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
US20040235892A1 (en) 2003-05-22 2004-11-25 Yujia Dai Indazole and benzisoxazole kinase inhibitors
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
TW200526777A (en) * 2003-11-12 2005-08-16 Combinatorx Inc Combinations for the treatment of proliferative diseases
JP3991983B2 (en) 2003-12-19 2007-10-17 日産自動車株式会社 Vehicle drive control device
US7004206B2 (en) 2004-01-29 2006-02-28 Viken James P Automatic fluid exchanger
WO2005082023A2 (en) 2004-02-23 2005-09-09 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
MXPA06014065A (en) * 2004-06-01 2007-01-31 Genentech Inc Antibody drug conjugates and methods.
CN109045307A (en) * 2004-06-01 2018-12-21 健泰科生物技术公司 Antibody-drug conjugates and method
JP4948413B2 (en) 2004-09-23 2012-06-06 ジェネンテック， インコーポレイテッド Cysteine engineered antibodies and conjugates
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
WO2006096861A2 (en) 2005-03-08 2006-09-14 Genentech, Inc. METHODS FOR IDENTIFYING TUMORS RESPONSIVE TO TREATMENT WITH HER DIMERIZATION INHIBITORS (HDIs)
US20060212956A1 (en) * 2005-03-14 2006-09-21 Genentech, Inc. Animal model of ligand activated HER2 expressing tumors
TW200716141A (en) * 2005-05-05 2007-05-01 Combinatorx Inc Compositions and methods for treatment for neoplasms
JP2006316040A (en) 2005-05-13 2006-11-24 Genentech Inc Herceptin(r) adjuvant treatment
PE20070207A1 (en) 2005-07-22 2007-03-09 Genentech Inc COMBINED TREATMENT OF TUMORS THAT EXPRESS HER
DK1934174T3 (en) 2005-10-07 2011-08-01 Exelixis Inc Acetidines as MEK inhibitors for the treatment of proliferative diseases
JP2009513642A (en) 2005-10-25 2009-04-02 アボット・ラボラトリーズ Formulation containing drug with low water solubility and method of using the same
US7781433B2 (en) 2006-04-26 2010-08-24 Piramed Limited Pharmaceutical compounds
RU2443706C2 (en) * 2006-04-26 2012-02-27 Дженентек, Инк. Pharmaceutical compounds
US20090098115A1 (en) 2006-10-20 2009-04-16 Lisa Michele Crocker Cell lines and animal models of HER2 expressing tumors
AU2007329352B2 (en) 2006-12-07 2013-01-17 F. Hoffmann-La Roche Ag Phosphoinositide 3-kinase inhibitor compounds and methods of use
CN101939006B (en) * 2007-09-12 2015-09-16 吉宁特有限公司 Phosphoinositide 3-kinase inhibitor compounds is combined and using method with chemotherapeutics
KR101781654B1 (en) 2009-03-12 2017-09-25 제넨테크, 인크. Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies

Also Published As

Publication number Publication date
US20170136026A1 (en) 2017-05-18
CL2009000559A1 (en) 2010-10-15
KR20180035923A (en) 2018-04-06
PL3269366T3 (en) 2020-07-27
JP2018052946A (en) 2018-04-05
HUE035182T2 (en) 2018-05-02
CA2990929A1 (en) 2009-09-24
KR101772304B1 (en) 2017-08-28
KR20150115951A (en) 2015-10-14
CN102036660B (en) 2015-05-06
PH12014502135A1 (en) 2015-06-29
CA3146422A1 (en) 2009-09-24
CN104873980A (en) 2015-09-02
WO2009117277A3 (en) 2010-04-29
EP2644194A3 (en) 2014-01-01
TW201611846A (en) 2016-04-01
KR20230054478A (en) 2023-04-24
DK2254571T3 (en) 2015-09-28
ES2629405T3 (en) 2017-08-09
RU2013147514A (en) 2015-04-27
IL234064B (en) 2020-05-31
EP2638907A2 (en) 2013-09-18
EP2638907A3 (en) 2014-05-14
CN110251670A (en) 2019-09-20
TWI527593B (en) 2016-04-01
DK2644204T3 (en) 2017-07-03
AU2009225877B2 (en) 2014-11-20
TWI574698B (en) 2017-03-21
ES2545977T3 (en) 2015-09-17
EP2644194A2 (en) 2013-10-02
MY188477A (en) 2021-12-13
JP5656823B2 (en) 2015-01-21
MX353429B (en) 2018-01-12
PL2644204T3 (en) 2017-09-29
WO2009117277A2 (en) 2009-09-24
RU2671489C2 (en) 2018-11-01
US8663643B2 (en) 2014-03-04
MY184496A (en) 2021-04-01
CN104873980B (en) 2019-07-19
CR11678A (en) 2010-12-13
CN102036660A (en) 2011-04-27
IL259499A (en) 2018-07-31
RU2510272C2 (en) 2014-03-27
IL295098A (en) 2022-09-01
RU2010142390A (en) 2012-04-27
EP3269366A3 (en) 2018-04-04
TW200942261A (en) 2009-10-16
UA127472C2 (en) 2023-09-06
PH12014502135B1 (en) 2015-06-29
PH12019501792A1 (en) 2021-03-22
TW201511771A (en) 2015-04-01
PH12014502133B1 (en) 2015-06-29
CA2990929C (en) 2022-04-12
JP2016040273A (en) 2016-03-24
PH12014502134A1 (en) 2015-06-29
RU2018136076A3 (en) 2021-10-25
JP2014132009A (en) 2014-07-17
TWI449536B (en) 2014-08-21
NZ587706A (en) 2012-12-21
UA108832C2 (en) 2015-06-25
NZ709293A (en) 2017-01-27
AR070865A1 (en) 2010-05-12
IL234065A0 (en) 2014-09-30
CA2716592C (en) 2018-02-27
NZ602675A (en) 2014-03-28
JP6705788B2 (en) 2020-06-03
CA2716592A1 (en) 2009-09-24
CN104888231B (en) 2019-05-17
SG10202104314YA (en) 2021-06-29
KR20190077616A (en) 2019-07-03
SG10201401942PA (en) 2014-08-28
KR102449659B1 (en) 2022-09-29
MY166446A (en) 2018-06-27
JP6016825B2 (en) 2016-10-26
EP3269366A2 (en) 2018-01-17
JP6388859B2 (en) 2018-09-12
KR20210131473A (en) 2021-11-02
ES2773510T3 (en) 2020-07-13
KR20100129318A (en) 2010-12-08
EP2644204A2 (en) 2013-10-02
TW201722475A (en) 2017-07-01
IL234064A0 (en) 2014-09-30
EP2644194B1 (en) 2017-04-19
CN104888232A (en) 2015-09-09
SI2644194T1 (en) 2017-08-31
MY166445A (en) 2018-06-27
PH12014502133A1 (en) 2015-06-29
PH12014502134B1 (en) 2015-06-29
ES2629067T3 (en) 2017-08-07
KR20160125535A (en) 2016-10-31
EP3269366B1 (en) 2020-01-15
EP3692988A2 (en) 2020-08-12
SI2644204T1 (en) 2017-08-31
NZ621433A (en) 2015-10-30
CN104888232B (en) 2019-05-10
HK1147444A1 (en) 2011-08-12
EP2254571A2 (en) 2010-12-01
HUE025507T2 (en) 2016-02-29
IL207894A (en) 2015-09-24
TWI675668B (en) 2019-11-01
US20140140993A1 (en) 2014-05-22
HUE035184T2 (en) 2018-05-02
JP2020147570A (en) 2020-09-17
SI2254571T1 (en) 2015-10-30
KR101751065B1 (en) 2017-06-26
RU2018136076A (en) 2020-04-13
CR20180483A (en) 2018-12-05
MX2010010168A (en) 2010-10-04
PL2254571T3 (en) 2015-11-30
MX2022000579A (en) 2022-02-10
BRPI0906181A2 (en) 2015-06-30
EP2644204B1 (en) 2017-04-19
AU2009225877A1 (en) 2009-09-24
IL207894A0 (en) 2010-12-30
MA32223B1 (en) 2011-04-01
US20190374547A1 (en) 2019-12-12
IL274393B (en) 2022-09-01
CN110251670B (en) 2023-11-14
EP2254571B1 (en) 2015-07-01
EP3692988A3 (en) 2020-10-14
US20120107302A1 (en) 2012-05-03
US20230201210A1 (en) 2023-06-29
IL234066A0 (en) 2014-09-30
IL274393A (en) 2020-06-30
CN104888231A (en) 2015-09-09
EP2644204A3 (en) 2014-02-12
ZA201006186B (en) 2011-11-30
IL234065B (en) 2018-06-28
JP2012500180A (en) 2012-01-05
KR20200113026A (en) 2020-10-05
PL2644194T3 (en) 2017-09-29
DK2644194T3 (en) 2017-07-03

Similar Documents

Publication Publication Date Title
IL274393A (en) Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
IL287292A (en) Cycteine engineering anti-cd79b antibodies and antibody-drug conjugates
HUS2000026I1 (en) Anti-CD79b antibodies and immunoconjugates and methods of use
IL205993A0 (en) Anti-b7h4 monoclonal antibody-drug conjugate and methods of use
EP2268673A4 (en) Polypeptide-polymer conjugates and methods of use thereof
EP2463371A4 (en) Sirna conjugate and preparation method thereof
LT2344478T (en) Cc-1065 analogs and their conjugates
HK1151791A1 (en) Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
EP2257316A4 (en) Contrast agents, methods for preparing contrast agents, and methods of imaging
EP2345660A4 (en) Anti-xdr-tb agent, anti-mdr-tb agent, and combined anti-tuberculous agent
ZA201100251B (en) Substituted 1-benzyl-cinnolin-4(1h)-one derivatives,preparation thereof,and therapeutic use thereof
GB0805726D0 (en) Regional sat nav voice option